Tie-2
信号通路图
研究领域
抑制剂选择性比较
Tie-2产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1361 |
MGCD-265 analogMGCD-265是一种有效的，多靶点，及ATP竞争性的c-Met和VEGFR1/2/3抑制剂，IC50分别为1 nM， 3 nM/3 nM/4 nM，也抑制Ron和Tie2。Phase 1/2。 |
c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, TAE-684, and RON inhibitor I. Columns, means; bars, SEMs (n = 3). The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
| S1577 |
Tie2 kinase inhibitorTie2 kinase inhibitor是SB-203580的优化产物，选择性作用于Tie2，IC50为0.25 μM，比作用于p38效果高200倍。 |
Inhibition of SVR (solid line) and MS1-VEGF (dashed line) cell survival by sunitinib (A) and Tie2 kinase inhibitor (B) and dose effect analysis of combined sunitinib and Tie2 kinase inhibitor (C). Cell survival was determined as described in Materials and Methods. Combination indices <1, =1, and >1 denote synergy, additivity, and antagonism, respectively. Values represent mean ?SE (n = 4). |
|
| S6412 |
AltiratinibAltiratinib (DCC-2701) 是有效的TRK, Met (c-Met), TIE2和VEGFR2激酶抑制剂，对TRKA, B和C的IC50分别为0.9 nM, 4.6 nM和0.8 nM。它抑制Met (c-Met)和Met (c-Met)突变体的IC50范围为0.3-6 nM。 |
||
| S7799 |
Pexmetinib (ARRY-614)Pexmetinib (ARRY-614)是一种有效的，口服生物可利用的，双重p38 MAPK/Tie-2抑制剂，其在HEK-293细胞中的IC50分别为4 nM/18 nM。Phase 1。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1361 |
MGCD-265 analogMGCD-265是一种有效的，多靶点，及ATP竞争性的c-Met和VEGFR1/2/3抑制剂，IC50分别为1 nM， 3 nM/3 nM/4 nM，也抑制Ron和Tie2。Phase 1/2。 |
c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, TAE-684, and RON inhibitor I. Columns, means; bars, SEMs (n = 3). The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
| S1577 |
Tie2 kinase inhibitorTie2 kinase inhibitor是SB-203580的优化产物，选择性作用于Tie2，IC50为0.25 μM，比作用于p38效果高200倍。 |
Inhibition of SVR (solid line) and MS1-VEGF (dashed line) cell survival by sunitinib (A) and Tie2 kinase inhibitor (B) and dose effect analysis of combined sunitinib and Tie2 kinase inhibitor (C). Cell survival was determined as described in Materials and Methods. Combination indices <1, =1, and >1 denote synergy, additivity, and antagonism, respectively. Values represent mean ?SE (n = 4). |
|
| S6412 |
AltiratinibAltiratinib (DCC-2701) 是有效的TRK, Met (c-Met), TIE2和VEGFR2激酶抑制剂，对TRKA, B和C的IC50分别为0.9 nM, 4.6 nM和0.8 nM。它抑制Met (c-Met)和Met (c-Met)突变体的IC50范围为0.3-6 nM。 |
||
| S7799 |
Pexmetinib (ARRY-614)Pexmetinib (ARRY-614)是一种有效的，口服生物可利用的，双重p38 MAPK/Tie-2抑制剂，其在HEK-293细胞中的IC50分别为4 nM/18 nM。Phase 1。 |
沪公网安备 31011502012800号